A股市場正圍繞“新型肺炎”展開:醫藥手遊股大漲、酒店航空影視股大跌
格隆匯1月20日丨因武漢新型肺炎病例猛增,A股市場今天的行情主要圍繞“新型肺炎”展開,醫藥(特別是流感概念股)板塊中,碩世生物、四環生物、萊茵生物、泰林生物、達安基因、科華生物、魯抗醫藥等超10股漲停,港股市場的東陽光藥更是一度漲超20%;“家裏宅”的手遊股普漲,三七互娛、電魂網絡等漲幅明顯;另一邊,旅遊酒店、餐飲、航空、影視甚至是白酒股普遍下跌,其中,橫店影視跌停,首旅酒店、萬達電影逼近跌停,中國電影、錦江酒店、中國國航、吉祥航空、春秋航空等均出現明顯下跌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.